Latest / Pharmacy Podcast Network / Asembia's Specialty Pharmacy Summit 2026 Rewind | Part 2/6

Transcript

Asembia's Specialty Pharmacy Summit 2026 Rewind | Part 2/6 · Pharmacy Podcast Network

• 0:03
  Speaker 1: Are systematic reviews taking months. There's a better way. Nested
• 0:09
  Speaker 1: Knowledge is an AI powered evidence synthesis platform built specifically
• 0:13
  Speaker 1: for life sciences teams working under tight timelines. From literature
• 0:17
  Speaker 1: search to metadata analysis, Everything happens in one place. Smart
• 0:21
  Speaker 1: screener evaluates thousands of studies against your criteria in minutes.
• 0:26
  Speaker 1: Smart ma extraction pulls quantitative data from tables and builds
• 0:30
  Speaker 1: your analysis automatically. Smart Critical Appraisal assesses bias using established
• 0:35
  Speaker 1: frameworks like JBI and sign with full transparency into every decision.
• 0:41
  Speaker 1: The result publication ready, Prisma diagrams, forest plots, and critical
• 0:46
  Speaker 1: appraisal visuals, all traceable, all auditible, and all generated from
• 0:50
  Speaker 1: a single platform. Whether you're in medical or regulatory affairs,
• 0:54
  Speaker 1: health economics and outcomes research, Nested Knowledge helps you produce
• 0:59
  Speaker 1: rigorous evidence synthesis in days, not months. Ready to see
• 1:03
  Speaker 1: how it works, visit nested hyphennoledge dot com to schedule
• 1:07
  Speaker 1: a demo. Nested Knowledge the standard and evidence synthesis.
• 1:21
  Speaker 2: You are listening to the global network of podcasters dedicated
• 1:24
  Speaker 2: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
• 1:41
  Speaker 1: Each year asembia's specialty Pharmacy Summit is at the epicenter
• 1:44
  Speaker 1: of the pharmacy industry, providing a unique opportunity for stakeholders
• 1:49
  Speaker 1: throughout the industry to understand challenges, generate solutions, and define
• 1:53
  Speaker 1: the future. This is the Pharmacy Podcast Networks ASSEMBIA twenty
• 1:58
  Speaker 1: twenty six rewind We're dedicated to bringing you inside coverage
• 2:04
  Speaker 1: of the pharmacy Nation's biggest events with on the street
• 2:07
  Speaker 1: style interviews with keynote speakers, attendees, exhibitors, and recurring guests
• 2:13
  Speaker 1: who make each year special. Stay tuned each week for
• 2:16
  Speaker 1: a new episode of this special six part series on
• 2:19
  Speaker 1: the ASSEMBIA twenty twenty sixth Summit, held this year in
• 2:22
  Speaker 1: Las Vegas.
• 2:28
  Speaker 3: Keith Kalmus is back on the Pharmacy Podcast Network here
• 2:32
  Speaker 3: at the ASSEMBIA twenty twenty six Keith, that's so good
• 2:34
  Speaker 3: to see.
• 2:35
  Speaker 4: It's great to see again. Todd.
• 2:36
  Speaker 3: He's just talking to Harry Travis about you and he's like,
• 2:39
  Speaker 3: oh my gosh, these guys are going everywhere and going
• 2:42
  Speaker 3: to different conferences and speaking at panels. And I said you,
• 2:46
  Speaker 3: I saw posts of you on LinkedIn at AMCP. Actually
• 2:50
  Speaker 3: you were at AMCP and you actually did not only
• 2:53
  Speaker 3: a presentation. But you've kind of are helping to elevate
• 2:56
  Speaker 3: standards in the usage of AI. I want you to
• 2:58
  Speaker 3: tell our listeners about that.
• 3:00
  Speaker 5: Absolutely, So speaking of Harry Travis, Harry put on the
• 3:03
  Speaker 5: AI pre conference at AMCP was a great conference overall,
• 3:06
  Speaker 5: particularly in the pre con. I gave a talk on
• 3:09
  Speaker 5: basically the rules for the road in AI in evidence synthesis.
• 3:15
  Speaker 5: So when you, as a pharmacist are prescribing a drug
• 3:17
  Speaker 5: that's obviously gone through the formula process, it's had a
• 3:20
  Speaker 5: lot of experts look at the clinical, epidemiological, and economic
• 3:24
  Speaker 5: evidence surrounding that drug and its class and its competitors,
• 3:29
  Speaker 5: and they've made the determination on what drug works best
• 3:32
  Speaker 5: and what indication in what patient population. The rules for
• 3:37
  Speaker 5: the road and that are changing, and there was actually
• 3:39
  Speaker 5: the release of a new set of standards called the
• 3:42
  Speaker 5: RAISE Guidance that stands for the Responsible Use of AI
• 3:45
  Speaker 5: and Evidence synthesis. It's a fast moving it's a fast
• 3:48
  Speaker 5: moving field. They just came out with them at the
• 3:50
  Speaker 5: end of last year. They've already gone through three iterations,
• 3:52
  Speaker 5: so they're really taking the whole concept of living guidance seriously.
• 3:56
  Speaker 5: And I gave a talk we are are no longer
• 4:00
  Speaker 5: speaking theoretically about the use of AI and eviden synthesis
• 4:03
  Speaker 5: for pharmacy. We're talking about how it's actually being deployed.
• 4:06
  Speaker 5: And I actually I spoke at the IPRE conference at
• 4:09
  Speaker 5: AMCP in twenty twenty five and it was like, how
• 4:12
  Speaker 5: might one how might one use AI when you're doing
• 4:16
  Speaker 5: evidence synthesis for P and T. Now it's okay, we're
• 4:18
  Speaker 5: doing it. What are the rules for the road. So
• 4:20
  Speaker 5: that's how quickly this has.
• 4:22
  Speaker 3: Moved rules of the road. And there was another term
• 4:26
  Speaker 3: that you use. First time I've really heard this, and
• 4:28
  Speaker 3: now it's gaining traction in specialty pharmacy. But throughout its horizon,
• 4:36
  Speaker 3: how do youse horizon scanning? Horizon scanning? So tell us
• 4:39
  Speaker 3: what that means?
• 4:40
  Speaker 5: Absolutely, that's a really it's another interesting use case for
• 4:43
  Speaker 5: AI in pharmacy. It's almost at the opposite end of
• 4:46
  Speaker 5: the spectrum from P and T. So I'll just note
• 4:50
  Speaker 5: for instance, and we were so happy to be a
• 4:53
  Speaker 5: partner with them in this, but the students during the
• 4:55
  Speaker 5: AMCPP and T competition use nested knowledge to make a
• 4:58
  Speaker 5: formulary recommendation, and that involved looking at every piece of evidence.
• 5:02
  Speaker 5: That involved going through all the literature, all the clinical
• 5:04
  Speaker 5: efficacy data, all the economic findings to make a determination
• 5:07
  Speaker 5: on whether or not a drug should be put on
• 5:08
  Speaker 5: formulary that has.
• 5:11
  Speaker 4: A human in the loop.
• 5:12
  Speaker 5: And AI is almost supplemental in that right, It's like there,
• 5:15
  Speaker 5: it's there to make you more efficient. If you go
• 5:18
  Speaker 5: look at the horizon scanning application, this is something that
• 5:21
  Speaker 5: I would say is fully automatable. It's something that you
• 5:24
  Speaker 5: can genuinely outsource to an AI and an aolog just
• 5:27
  Speaker 5: run this whole function for you. So let's say you
• 5:31
  Speaker 5: know you're you're responsible for understanding what the way of
• 5:34
  Speaker 5: the land is in a in a specific therapeutic area,
• 5:37
  Speaker 5: you know, fast moving therapeutic area. Let's say you know
• 5:41
  Speaker 5: metabolic dysfunction OBCD, diabetes, MASH or or oncology right like NSCLC.
• 5:47
  Speaker 5: There's there's so many new therapies in the pipeline. It's
• 5:50
  Speaker 5: it's an overwhelming amount of of therapies and obviously you
• 5:55
  Speaker 5: can't ignore them. Maybe one of these is going to
• 5:58
  Speaker 5: save some of your page. You know, the people you're
• 6:01
  Speaker 5: responsible for is life, or save your plan a bunch
• 6:03
  Speaker 5: of money, or or really transform the field. How do
• 6:06
  Speaker 5: you stay on top of that. That's really what the
• 6:08
  Speaker 5: concept of horizon scanning is. That used to be a
• 6:11
  Speaker 5: fully manual process. You would have to go and look at,
• 6:13
  Speaker 5: like what what drugs are in the pipeline, look at
• 6:16
  Speaker 5: look at a clinical trostuc CoV and understand, you know,
• 6:18
  Speaker 5: what are the what are the indicated patients, what what's
• 6:21
  Speaker 5: the inclusion exclusion criteria, what are the end points? You know,
• 6:25
  Speaker 5: primary secondary exploratory, and you have to go in and
• 6:27
  Speaker 5: download individual records from clinical trostuc up, look at the indication,
• 6:31
  Speaker 5: look at the sponsor, really understand what what molecule is
• 6:34
  Speaker 5: being used and see if it would be relevant to
• 6:36
  Speaker 5: your formulae.
• 6:37
  Speaker 4: Now you can have an AI do all that.
• 6:38
  Speaker 5: You can have an AI go and pull all those records,
• 6:41
  Speaker 5: build them into machine readable uh uh displays, and then
• 6:46
  Speaker 5: have an AI extract who's the manufacturer, what stages, an at,
• 6:50
  Speaker 5: what's the indicated population, and you also understand how you
• 6:55
  Speaker 5: can then do a class review. Right, you're almost pre
• 6:57
  Speaker 5: building a sort of comparative clinical efficacy. And now that
• 7:00
  Speaker 5: you would do by understanding what that patient population is,
• 7:03
  Speaker 5: can you do an apples to apples comparison?
• 7:05
  Speaker 4: So are the end points going to be the same
• 7:06
  Speaker 4: as the molecules currently on the market.
• 7:08
  Speaker 5: And yeah, I would. I would say for horizon scanning,
• 7:11
  Speaker 5: we're there. That's something you you as a as a
• 7:13
  Speaker 5: pharmacist or or a plan exactor, whatever could could set
• 7:16
  Speaker 5: up tomorrow and just have a good read on what's
• 7:20
  Speaker 5: coming in the.
• 7:21
  Speaker 4: Next two, three, four years.
• 7:23
  Speaker 3: How do people decide how to engage when to engage
• 7:30
  Speaker 3: the nested knowledge team? Like how how are because I
• 7:35
  Speaker 3: at automatically think of content developers, we absolutely the entire
• 7:40
  Speaker 3: infrastructure of evidence space podcasting is setting on top of
• 7:44
  Speaker 3: nested knowledge, access to information in the right information and
• 7:48
  Speaker 3: then future information that comes out you're grabbing it, which
• 7:51
  Speaker 3: I love. But for a specialty pharmacy or for an association,
• 7:56
  Speaker 3: or for you know, a CE developer, like how how
• 8:01
  Speaker 3: has nested knowledge leveraged?
• 8:03
  Speaker 5: That's a great question and it really depends on the
• 8:05
  Speaker 5: specific use cases. So if you're in you know, especially
• 8:08
  Speaker 5: pharmacy that you're talking about, like when you need to
• 8:10
  Speaker 5: do that class review, when you need to understand what
• 8:12
  Speaker 5: the landscape is, when you need to understand what the
• 8:14
  Speaker 5: comparative efficacy is or what the epidate is going to be.
• 8:16
  Speaker 5: You know, how many patients. Am I going to have
• 8:19
  Speaker 5: to give this to right in my specific population? That's
• 8:21
  Speaker 5: an epidemiological review. That's an epidemiological review. We're going to
• 8:24
  Speaker 5: go find the incidents and prevalence and we cannap that
• 8:26
  Speaker 5: onto you know, maybe the racial or or age demographics
• 8:29
  Speaker 5: of your specific population that you're coming.
• 8:32
  Speaker 4: So that's that's when you would use it for for.
• 8:34
  Speaker 5: A pharmacist, for a society, that's that's almost a whole.
• 8:39
  Speaker 4: Other end of the speculating.
• 8:41
  Speaker 5: I've worked with some some UH societies to develop guidelines.
• 8:45
  Speaker 5: That's that's a core functionality of a lot of these societies.
• 8:48
  Speaker 5: So the American Historical Association did some guidelines in nestonolagche
• 8:52
  Speaker 5: work in some other guide UH UH societies to develop
• 8:55
  Speaker 5: guidelines and those those are systematic reviews. Those are understanding
• 9:00
  Speaker 5: the clinical landscape, you know, what therapies and interventions are
• 9:02
  Speaker 5: available to clinicians to deploy, and really understanding what patient
• 9:07
  Speaker 5: populations those should be used in. Right, That's that's all
• 9:10
  Speaker 5: guideline is that's supported bias systematic of You often buy
• 9:14
  Speaker 5: a meta analysis actually if it's in if it's in
• 9:16
  Speaker 5: a well established therapeutic area and you want to understand
• 9:18
  Speaker 5: you know what is going to give patients the most benefit.
• 9:21
  Speaker 5: That is when a meta analysis would come into play.
• 9:24
  Speaker 5: So it really runs the gamut. Speaking of the you know,
• 9:28
  Speaker 5: the whole evidence based podcasting look finding references, this is
• 9:32
  Speaker 5: something that you this is something that you don't want
• 9:34
  Speaker 5: to rely on lllms for I'm a huge fan of lllms.
• 9:37
  Speaker 5: I use them every week and they can really help
• 9:41
  Speaker 5: with a lot of stuff. But you don't want to
• 9:45
  Speaker 5: source your references from lms because they will give you
• 9:47
  Speaker 5: fake studies. They will literally make up studies and feed
• 9:50
  Speaker 5: them to you. So use them to do your first draft.
• 9:53
  Speaker 5: Use them like I use them again every day.
• 9:55
  Speaker 4: I use them.
• 9:56
  Speaker 5: Don't use them to find references. When you're finding evidence,
• 9:59
  Speaker 5: do in a traditional manner that is then AI augmented.
• 10:03
  Speaker 4: So definitely go to all the same traditional databases you
• 10:05
  Speaker 4: would go to. You know, you can have you can
• 10:07
  Speaker 4: have AI help you draft your query that's going to
• 10:09
  Speaker 4: go to those databases, But you want to go to
• 10:10
  Speaker 4: the databases specifically. You want to make sure that.
• 10:12
  Speaker 5: You're preserving the audit trail when you're finding that evidence,
• 10:15
  Speaker 5: whether it's in podcasting or in formulating on this or
• 10:18
  Speaker 5: on the manufacturer side, right like we should all be
• 10:20
  Speaker 5: operating from the same principles of reproducibility and provenance and replicability.
• 10:27
  Speaker 5: You know, the biggest thing that I can say is
• 10:31
  Speaker 5: you should be able to have someone else do the
• 10:35
  Speaker 5: same research that you did and if even if they
• 10:38
  Speaker 5: don't come to the same conclusion, they need to understand.
• 10:40
  Speaker 4: Why you came to your conclusion, the data you're relying on,
• 10:43
  Speaker 4: and vice versa.
• 10:44
  Speaker 5: So that's that's all I say for the whole the
• 10:46
  Speaker 5: whole evidence base is replicability.
• 10:50
  Speaker 3: Keith Kalamus Nested Knowledge. We are so excited that you're
• 10:55
  Speaker 3: part of the network and giving us your support and
• 10:57
  Speaker 3: your insights. Can't wait to have you back on this
• 11:00
  Speaker 3: week in Pharmacy.
• 11:01
  Speaker 4: Thanks for having me Todd, It's great to see you
• 11:02
  Speaker 4: as always.
• 11:06
  Speaker 6: Hey, this is Hannahbaxer from the Deadham Group and you're
• 11:09
  Speaker 6: listening to Pharmacy Podcast.
• 11:13
  Speaker 3: Hannah Baxter Andrew Rove deed Ham Group. Welcome to the
• 11:17
  Speaker 3: Assembia post show. How are you good doing well?
• 11:20
  Speaker 6: Thank you?
• 11:20
  Speaker 7: How are you happy to be here?
• 11:22
  Speaker 3: All right, let's get right into this. What do you
• 11:25
  Speaker 3: guys do in specialty pharmacy? Why do you invest the
• 11:27
  Speaker 3: time to come to ASSEMBIA.
• 11:29
  Speaker 4: Thanks.
• 11:30
  Speaker 6: Well, good question to start us off with. So I
• 11:33
  Speaker 6: can tell you a little bit about the DEADHIM group
• 11:35
  Speaker 6: where a life science consulting from So we focus on
• 11:38
  Speaker 6: market access strategy and commercial strategy. So for us being
• 11:42
  Speaker 6: here and partnering with m MIT assistant company under the
• 11:45
  Speaker 6: Nocella branch, we're looking to help clients facilitate different relationships,
• 11:50
  Speaker 6: support with any key questions that are coming up from
• 11:53
  Speaker 6: industry insights that we're hearing on our side from kind
• 11:57
  Speaker 6: of different stakeholders across the ecosystem. And then as we
• 12:00
  Speaker 6: help kind of the information flow as well and provide
• 12:02
  Speaker 6: strategic guidance.
• 12:04
  Speaker 7: And then Andrew, Yes, and I'm an m MIT. We're
• 12:07
  Speaker 7: a analytics and data company. I work on the market
• 12:10
  Speaker 7: research and insights side of the organization. So what we
• 12:13
  Speaker 7: do is put together exactly that market research as well
• 12:15
  Speaker 7: as insights to understand coverage policies, claims, data as things
• 12:19
  Speaker 7: like that, just to help manufacturers understand what's going on
• 12:22
  Speaker 7: from a market access perspective.
• 12:25
  Speaker 3: Andrew, when you look at the data thirty thousand foot view,
• 12:29
  Speaker 3: are there any parts of rare disease that you're like, Wow,
• 12:35
  Speaker 3: there's an opportunity to improve the access, getting the patient
• 12:39
  Speaker 3: started on the therapy, keeping the patient on the therapy.
• 12:41
  Speaker 3: Are there any stories that you've seen, because data for
• 12:45
  Speaker 3: the right analysis and for the right consulting group can
• 12:48
  Speaker 3: be a blinding light where you like there it is,
• 12:50
  Speaker 3: there's the issue. Share with our listeners some of your insights.
• 12:53
  Speaker 8: Definitely.
• 12:54
  Speaker 7: So rare disease is particularly interesting. Rare disease is growing
• 12:58
  Speaker 7: tremendously tons at this point. There's tons of new drugs
• 13:01
  Speaker 7: coming out in the rare disease space as technology gets
• 13:03
  Speaker 7: better or the science is just the breakthrough is incredible
• 13:07
  Speaker 7: at this point. So we have a lot of new
• 13:08
  Speaker 7: technologies coming out that allow for rare diseases that have
• 13:10
  Speaker 7: never even previously been identified to now be treatable. The
• 13:14
  Speaker 7: problem is exactly what you just outline. From a market
• 13:16
  Speaker 7: access perspective, a rare disease by definition is only a
• 13:20
  Speaker 7: small amount of patients that have the disease, which means
• 13:23
  Speaker 7: that consequently, these new therapies that are very expensive to
• 13:25
  Speaker 7: develop are very expensive. So from a market access perspective,
• 13:29
  Speaker 7: what our clients really need to do is to make
• 13:31
  Speaker 7: sure that the patients with these diseases can have access
• 13:34
  Speaker 7: to their therapies at a reasonable price that they can
• 13:36
  Speaker 7: afford and can stay on these brands. So manufacturers do
• 13:39
  Speaker 7: this in tons of different ways. Patient support program comes
• 13:43
  Speaker 7: to mind in particular. What they do with this is
• 13:45
  Speaker 7: to help their patients get on brands and stay on brands.
• 13:48
  Speaker 7: Actually provide their own support, just the financial support, logistics support.
• 13:53
  Speaker 7: If you're trying to do a prior authorization and it
• 13:55
  Speaker 7: gets denied, they can actually work with the patient as
• 13:58
  Speaker 7: well as the HDP to make sure that you do
• 13:59
  Speaker 7: get on the brand. So that's just one tactic of
• 14:02
  Speaker 7: frankly dozens that manufacturers do to help patients get on there.
• 14:06
  Speaker 7: But the rare disease, like I said before, it's growing
• 14:09
  Speaker 7: probably about as fast as any area within pharmaceuticals today.
• 14:12
  Speaker 3: Hannah, how is the manufacture of these rare disease disease
• 14:17
  Speaker 3: medications super expensive? Sometimes limited distribution. They're very choosy as
• 14:24
  Speaker 3: to what specially farmercies they're they're they're working with. How
• 14:27
  Speaker 3: has the how has Baxter? How have you and the
• 14:31
  Speaker 3: Denim group really identified barriers for the manufacturer and to
• 14:37
  Speaker 3: bring information back to them and saying here's an opportunity
• 14:40
  Speaker 3: to improve. Yeah, that's a great question.
• 14:43
  Speaker 6: I think with the world of distribution models, channel ecosystems,
• 14:47
  Speaker 6: enterprise entities, with the kind of quick evolution of what
• 14:50
  Speaker 6: we've seen with partnerships acquisitions, it's very important to look
• 14:53
  Speaker 6: at the distribution channel. So when we think about a
• 14:56
  Speaker 6: limited distribution network or something broader, we're assessing what do
• 15:00
  Speaker 6: the vendors or what can they provide to the manufacturer
• 15:03
  Speaker 6: to help them better understand the population. And then for
• 15:06
  Speaker 6: the manufacturer, why does that particular vendor walk well as
• 15:08
  Speaker 6: a partnership. So it's evaluating both sides of the puzzle.
• 15:11
  Speaker 6: Thinking about it from the distribution side, how can they
• 15:13
  Speaker 6: help the manufacturer target the right populations, the right prescribers,
• 15:17
  Speaker 6: sites of care. And then for the manufacturers, it's helping
• 15:20
  Speaker 6: choose the right partner, So what type of support can
• 15:23
  Speaker 6: they offer, what type of data that's unique to them?
• 15:26
  Speaker 6: So it's a two way system. So it's making sure
• 15:28
  Speaker 6: women we're thinking about strategy when we're thinking about who
• 15:31
  Speaker 6: that limited distributor should be. Maybe it's one two more
• 15:34
  Speaker 6: than that. What's the appropriate side? What are the trade
• 15:36
  Speaker 6: offs to making that decision, Because it's a very critical
• 15:39
  Speaker 6: point to get the product from obviously manufacturing down to
• 15:43
  Speaker 6: the right prescriber sites.
• 15:46
  Speaker 3: So, Andrew, how has the biosimilar and selling gene therapy
• 15:51
  Speaker 3: explosion onto the market, especially within the last eighteen months
• 15:55
  Speaker 3: two years, we're hearing that by twenty thirty there's going
• 15:58
  Speaker 3: to be an additional two one hundred of these selling
• 16:02
  Speaker 3: gene therapies on the market. How has that impacted kind
• 16:05
  Speaker 3: of the research that you're developing as well as the
• 16:07
  Speaker 3: attention that's being drawn towards these therapies.
• 16:10
  Speaker 7: Definitely tons of attention to biosimilars in the last exactly
• 16:13
  Speaker 7: what you said two to three years, maybe five years,
• 16:16
  Speaker 7: but honestly two to three has been a big explosion
• 16:18
  Speaker 7: right now and it is expected to increase in the
• 16:20
  Speaker 7: foreseable future. The two biosimilars that come to mind that
• 16:24
  Speaker 7: really causes explosion, I don't know if cause it or
• 16:26
  Speaker 7: more of an effect are Stillara and Humor, massive brands
• 16:29
  Speaker 7: that have tons of thas, very high utilization, very successful brands,
• 16:33
  Speaker 7: and the most successful brands that have ever been developed.
• 16:37
  Speaker 7: Loss of exclusivity happened recently, so biosimilars came to the market.
• 16:40
  Speaker 4: For both of these brands.
• 16:42
  Speaker 7: There are between five and ten biosimilars that have been improved,
• 16:45
  Speaker 7: maybe even more for humor. So this is again it's
• 16:48
  Speaker 7: going to be key driver of biosimilars, and there's been
• 16:51
  Speaker 7: tons of attention to it from the payer landscape as
• 16:53
  Speaker 7: well as manufacturers just to understand what it means, because
• 16:56
  Speaker 7: we haven't seen biosimilars come to this much attention ever before.
• 17:00
  Speaker 7: That means that payers are prioritizing different biosimilar first policies,
• 17:04
  Speaker 7: requiring you to step through a biosimilar prior to getting
• 17:07
  Speaker 7: on the originator brands. You have to go through a
• 17:08
  Speaker 7: humor biosimilar prior to the humera itself. At times, and
• 17:13
  Speaker 7: more so than that, we've actually seen payers go through
• 17:15
  Speaker 7: vertical integration in order to further prioritize these biosimilar so
• 17:19
  Speaker 7: partnering with biosimilar manufacturers.
• 17:22
  Speaker 4: To just do just that.
• 17:23
  Speaker 7: They'll prefer that particular biosimilar first and there's a partnership
• 17:26
  Speaker 7: with the manufacturer that's beneficial for everybody. So the biosimilar trend,
• 17:31
  Speaker 7: it's been around for not a while five years or so,
• 17:33
  Speaker 7: by the last two or three years, massive explosion with
• 17:35
  Speaker 7: these two brands. Zolar recently came off Patent two, so
• 17:39
  Speaker 7: there's a biosimilar for that, plenty of other brands as
• 17:42
  Speaker 7: well to retuxin things like that, and it's just going
• 17:45
  Speaker 7: to increase. But they're looking at the humor and still
• 17:47
  Speaker 7: are a blueprint for what it's going to mean for
• 17:49
  Speaker 7: the future. Is the key strategy we're seeing from manufacturers today.
• 17:54
  Speaker 3: Hannah, how has women's health specifically from a research perspective
• 18:00
  Speaker 3: become risen and are getting is getting more attention than
• 18:05
  Speaker 3: what it was. I remember I don't remember much being
• 18:08
  Speaker 3: talked about in fertility six to seven years ago. It's
• 18:11
  Speaker 3: there's so much happening now, specifically in women's health. Talk
• 18:15
  Speaker 3: to us about your research and the opportunities that you're
• 18:17
  Speaker 3: bringing to the manufacturers but then also to the outlets. Yeah,
• 18:22
  Speaker 3: that's a good question.
• 18:22
  Speaker 6: We've definitely seen kind of search and therapies as it
• 18:24
  Speaker 6: relates to women's health, and I think it's kind of
• 18:26
  Speaker 6: across the board, whether we're thinking about fertility, O, varying cancer,
• 18:30
  Speaker 6: different types of cancers as well. So I think it's
• 18:33
  Speaker 6: great to see that much clinical development, the amount.
• 18:36
  Speaker 3: Of products in clinical trials that's.
• 18:37
  Speaker 6: Being evaluated to suddenly helpful to kind of bring more
• 18:40
  Speaker 6: to market in terms of kind of what we want
• 18:42
  Speaker 6: to think about from an access strategy point is the
• 18:44
  Speaker 6: more products that come available, it does make it more
• 18:47
  Speaker 6: of a competitive landscape. So how do we think about
• 18:49
  Speaker 6: the right access channels? Kind of what access looks like,
• 18:52
  Speaker 6: what does good look like? We were talking a little
• 18:54
  Speaker 6: bit about biosimilar so obviously with that management comes in.
• 18:57
  Speaker 6: So as a therapy area or category gets more crowded,
• 19:02
  Speaker 6: we want to make sure that the access restrictions are appropriate,
• 19:05
  Speaker 6: that patients can get the right medically necessary products. So
• 19:09
  Speaker 6: it's great to see this much innovation, and what we
• 19:10
  Speaker 6: want to think about is how do we keep access open.
• 19:13
  Speaker 6: How do we support manufacturers, target key strategies with whether
• 19:17
  Speaker 6: we're talking about payers, providers, to make sure that those
• 19:20
  Speaker 6: lines of access stay open affordable for patients as well.
• 19:24
  Speaker 6: So it's thinking about it from a few different angles
• 19:26
  Speaker 6: from an access strategy perspective to make sure with all
• 19:29
  Speaker 6: these products coming to market in new spaces, access remains open.
• 19:33
  Speaker 6: And yes, it's good to have options, but what we
• 19:35
  Speaker 6: want to make sure is those options don't translate to
• 19:37
  Speaker 6: restrictions because there's a number of products available all right.
• 19:42
  Speaker 3: Assembia twenty twenty six. This has been a rocket ship
• 19:46
  Speaker 3: of activity. I want to thank m MIT and the
• 19:49
  Speaker 3: Denim Group for being part of the post show. Andrew Hannah,
• 19:53
  Speaker 3: thanks for being here.
• 19:54
  Speaker 4: Thanks for having us.
• 19:55
  Speaker 8: It's been a pleasure.
• 19:56
  Speaker 6: Thank you so much.
• 20:00
  Speaker 3: Here with Heather Bomb from your IRAQ. Heather, is so
• 20:04
  Speaker 3: good to see you again. Great to be here. Is
• 20:06
  Speaker 3: this turning into a tradition for us? Because you were
• 20:08
  Speaker 3: on our show last year? I was?
• 20:10
  Speaker 9: I certainly hope so it is. I love If I
• 20:13
  Speaker 9: get invited back next year.
• 20:14
  Speaker 3: Probably will. All Right, your IRAQ extremely important organization helping
• 20:19
  Speaker 3: to keep standards high in specialty pharmacy, all over pharmacy.
• 20:23
  Speaker 3: But let's just focus on specialty. You had a new
• 20:27
  Speaker 3: program that you kind of gave me a little bit
• 20:29
  Speaker 3: of a hint about last year that's now become full power.
• 20:33
  Speaker 3: Talk to us about that. What is what's happening with
• 20:35
  Speaker 3: your rec right now?
• 20:36
  Speaker 10: Yeah?
• 20:36
  Speaker 9: So you know, our specialty pharmacy accreditation is clearly one
• 20:41
  Speaker 9: of our most popular programs and it's where my team,
• 20:44
  Speaker 9: the Pharmacy team, spends most of their time. Every three
• 20:46
  Speaker 9: to five years or so, we revise the standards and
• 20:50
  Speaker 9: we do that by bringing together industry experts. What's important
• 20:54
  Speaker 9: what's changed, you know, how should we revise the standards,
• 20:57
  Speaker 9: And we were in the process of that really all
• 20:59
  Speaker 9: through twenty two. In fact, we had a big session
• 21:02
  Speaker 9: that we hosted at ASSEMBA last year taking advantage of
• 21:05
  Speaker 9: everybody in specialty pharmacy being here. Got some feedback. One
• 21:09
  Speaker 9: of the things we learned through that process was actually
• 21:12
  Speaker 9: our standards pretty much.
• 21:14
  Speaker 3: Were already hitting the mark. So we made a few.
• 21:17
  Speaker 9: Changes with the revision, and the current version of the program,
• 21:21
  Speaker 9: which is version six tot zero, is released. That's what
• 21:24
  Speaker 9: organizations are being accredited under now. But it's not huge
• 21:28
  Speaker 9: changes because the industry really again informed us that our
• 21:33
  Speaker 9: standards were hitting the mark. A few things we updated
• 21:36
  Speaker 9: some of the telephone performance metrics, added a few things there,
• 21:40
  Speaker 9: and then other things like dispensing accuracy, really shifting the
• 21:46
  Speaker 9: focus of that to promoting safe dispensing and promoting a
• 21:51
  Speaker 9: culture where reporting happens and can be addressed versus a
• 21:56
  Speaker 9: punitive approach to when an error happens. So some kind
• 21:59
  Speaker 9: of new shifting of concepts, but not you know, wholesale
• 22:03
  Speaker 9: new concepts, and we're getting really good feedback on the
• 22:06
  Speaker 9: release of that too.
• 22:07
  Speaker 3: All right, So you also have dug deeper into rare
• 22:12
  Speaker 3: DISEASEPA siscivity. I can't say that. See, that's why I'm
• 22:16
  Speaker 3: not a pharmacist. Hey, yes, speacivity and kind of tell
• 22:20
  Speaker 3: our listeners about that too, because that's very important.
• 22:22
  Speaker 9: Sure, we've had a rare disease designation and now certification
• 22:26
  Speaker 9: program for several years. It's one of the places where
• 22:29
  Speaker 9: we are seeing more growth in the accreditation space. So
• 22:32
  Speaker 9: specialty pharmacies that are dispensing in orphan drugs to treat
• 22:39
  Speaker 9: rare diseases that really require even more clinical care and
• 22:43
  Speaker 9: even more patient support than the complex specialty therapies that
• 22:47
  Speaker 9: we can quote traditionally talk about. We have a set
• 22:49
  Speaker 9: of standards for that too, and so you have the
• 22:52
  Speaker 9: specialty pharmacy accreditation on top of that, you can seek
• 22:56
  Speaker 9: the rare disease certification. It's not for all specialty pharmacies.
• 23:00
  Speaker 9: It's really only for those that are focusing on these
• 23:04
  Speaker 9: very specific orphan medications. But we're continuing to see some
• 23:08
  Speaker 9: growth in the number of specialty pharmacies that are heading
• 23:12
  Speaker 9: in that direction and seeking that certification.
• 23:15
  Speaker 3: All right, So the big topic here at ASMBIA one
• 23:21
  Speaker 3: of the top three and definitely. In our theme is
• 23:25
  Speaker 3: artificial intelligence specifically in specialty and what that means, how
• 23:28
  Speaker 3: that differentiates from long term care, compounding or community pharmacy.
• 23:33
  Speaker 3: Talk to us about the accreditation of what it is
• 23:36
  Speaker 3: to use AI in specialty pharmacy.
• 23:38
  Speaker 5: Yeah.
• 23:39
  Speaker 9: Absolutely, So in September of twenty twenty five, Yurak launched
• 23:44
  Speaker 9: the first national AI and Healthcare accreditation. It was pretty
• 23:49
  Speaker 9: natural for us. So, yes, we do a lot of
• 23:52
  Speaker 9: work in the pharmacy space, but we're a national accreditor
• 23:54
  Speaker 9: across healthcare and a lot of the healthcare organizations that
• 23:58
  Speaker 9: we already credit, we're saying, hey, you know, we're using
• 24:00
  Speaker 9: AI and we could use guidelines, standards as to how
• 24:05
  Speaker 9: to you know, implement, test, monitor, train our staff all
• 24:10
  Speaker 9: of that. So, like we do for any program, we
• 24:13
  Speaker 9: brought together industry experts and said, all right, what should
• 24:16
  Speaker 9: this program look like? And it included users of AI,
• 24:22
  Speaker 9: AI systems and healthcare and also developers, and we actually
• 24:25
  Speaker 9: pretty quickly realized the program should not only focus on
• 24:29
  Speaker 9: users but also developers. So it's a modular program and
• 24:32
  Speaker 9: there are some foundational standards in it, but it has
• 24:37
  Speaker 9: modules to say hey, and so we have some organizations
• 24:39
  Speaker 9: seeking accreditation right now, and they develop and then they
• 24:43
  Speaker 9: also use the AI systems that they they develop, so
• 24:47
  Speaker 9: they're developers and users. And then we have some others
• 24:49
  Speaker 9: that are, hey, we're using AI systems that someone else
• 24:52
  Speaker 9: is developing for us.
• 24:53
  Speaker 4: How do we do that?
• 24:54
  Speaker 9: And then we have developers, Hey, we just develop and
• 24:58
  Speaker 9: we want to partner with organizations to use our AI systems.
• 25:02
  Speaker 3: So it's so it's fascinating. It's been a lot of
• 25:05
  Speaker 3: fun think where it's all going. And the standards are
• 25:08
  Speaker 3: so important to keep to keep things in check so
• 25:12
  Speaker 3: that we can make improvements. If you don't have some
• 25:14
  Speaker 3: way to check on how you're developing higher abilities to
• 25:20
  Speaker 3: develop deliver care through those standards, it's it's hard to
• 25:24
  Speaker 3: map it out, especially with the creativity of AI.
• 25:27
  Speaker 9: Too exactly, and it's moving so fast, right, But that's
• 25:30
  Speaker 9: why accreditation works. So you know, really, as a country,
• 25:34
  Speaker 9: we're struggling with regulations around AI. There have been so
• 25:38
  Speaker 9: much there has been so much legislation on the federal level,
• 25:41
  Speaker 9: on the state level, and I mean think about that,
• 25:44
  Speaker 9: different states having different regulations. How could anybody, particularly a
• 25:47
  Speaker 9: national healthcare provider, you know, maintain compliance with all of that.
• 25:51
  Speaker 9: So accreditation just works because we can offer a national
• 25:56
  Speaker 9: healthcare accreditation that can apply to really any kind of
• 26:01
  Speaker 9: AI system because we're not saying, hey, you have to
• 26:04
  Speaker 9: do X, Y and z, it's saying it's a structure, right, Hey,
• 26:07
  Speaker 9: you need to make sure that you are testing before
• 26:11
  Speaker 9: you implement your training your staff so that they know
• 26:15
  Speaker 9: what the system's intended use is and what your expected
• 26:19
  Speaker 9: outcome should be. And if you don't get that outcome,
• 26:22
  Speaker 9: what do you do about it? Who are you reporting
• 26:24
  Speaker 9: back to, what does the monitoring look like, how are
• 26:26
  Speaker 9: you disclosing to other stakeholders? Just all of that infrastructure.
• 26:31
  Speaker 9: But that infrastructure can fit to really any kind of
• 26:34
  Speaker 9: AI system that is being used in the healthcare setting.
• 26:36
  Speaker 9: It doesn't have to be so specific. And we have
• 26:39
  Speaker 9: the ability to circle back with our advisory group and
• 26:44
  Speaker 9: make potential updates to the standards in a way that
• 26:47
  Speaker 9: regulations don't really have that flexibility. So accreditation just works
• 26:52
  Speaker 9: in this space.
• 26:54
  Speaker 3: Heather Bom, thank you so much for participating in the
• 26:58
  Speaker 3: Access to Pharmacy ASSEMBIA show. We really appreciate you being
• 27:01
  Speaker 3: here again, so thank you. It's been great being here. Thanks.
• 27:07
  Speaker 10: Hey, there, Jeremy Richards and CEO with gift Health. You're
• 27:10
  Speaker 10: listening to the pharmacy podcast.
• 27:14
  Speaker 3: Hey Technology, My goodness. It's really transforming. Been in this
• 27:18
  Speaker 3: industry for over twenty years. It's moving through benefit coordination
• 27:23
  Speaker 3: and patient engagement, communication, direct to patient models. It's almost
• 27:28
  Speaker 3: in some ways it's like the wild West, but it's
• 27:31
  Speaker 3: a controlled madness of things that are happening. We need
• 27:35
  Speaker 3: organizations that really center on patient first, medication management and treatment.
• 27:42
  Speaker 3: I'm so glad to meet up with you, Jeremy with
• 27:45
  Speaker 3: gift Health. How you doing here at Assembia?
• 27:47
  Speaker 8: Doing well?
• 27:48
  Speaker 10: It's a crazy busy time. It's really interesting to be
• 27:52
  Speaker 10: here when the industry is just evolving so quickly. But
• 27:55
  Speaker 10: we're having a great time. We're really excited to be
• 27:57
  Speaker 10: leading the charge.
• 27:59
  Speaker 3: Just in case our listeners who didn't get to attend
• 28:02
  Speaker 3: Assembia didn't get to come to your booth, give us
• 28:06
  Speaker 3: a summary. What is gift Health.
• 28:08
  Speaker 10: So Gift Health we were established in twenty twenty and
• 28:11
  Speaker 10: we are a digital pharmacy and we are really focused
• 28:14
  Speaker 10: on end end solution where we eliminate the handoffs right
• 28:18
  Speaker 10: where we can take care of patients end to end
• 28:20
  Speaker 10: and really presenting that presenting that option to the industry
• 28:25
  Speaker 10: and just sharing what we have and taking that from
• 28:28
  Speaker 10: taking that from a perspective of you know, developing, developing
• 28:32
  Speaker 10: this world where there were you know, so many handoffs
• 28:35
  Speaker 10: and there were so many issues that patients had, and
• 28:37
  Speaker 10: now we can we can really help patients, we can
• 28:40
  Speaker 10: help providers, we can help manufacturers to really to consolidate that,
• 28:46
  Speaker 10: to consolidate that journey and really have a full service partner.
• 28:51
  Speaker 3: We're in an age of and there's something good about this,
• 28:54
  Speaker 3: and then there's something bad about this. We could actually
• 28:57
  Speaker 3: talk for hours. Jeremy on the philosophy of speed to information,
• 29:01
  Speaker 3: access to information. Sometimes the consumer getting access to too
• 29:08
  Speaker 3: much information will confuse things, whereas Gift Health is really
• 29:13
  Speaker 3: putting these guardrails around an opportunity for patients to come
• 29:17
  Speaker 3: back to give health, ask lots of good questions and
• 29:20
  Speaker 3: not have to go through silos and not going to
• 29:22
  Speaker 3: have to go through a bunch of data they don't understand.
• 29:25
  Speaker 3: So talk to us about that ecosystem that you guys
• 29:28
  Speaker 3: have created.
• 29:30
  Speaker 10: So what's interesting is I feel like the industry, for
• 29:32
  Speaker 10: a long time, and in a lot of great ways,
• 29:34
  Speaker 10: has really focused on the script journey, the prescription journey.
• 29:37
  Speaker 10: But now we are really hyper focused on the patient journey, right,
• 29:41
  Speaker 10: what is that experience like, Like, how do you engage
• 29:43
  Speaker 10: the patient?
• 29:44
  Speaker 8: How do you do it immediately? How do you do
• 29:46
  Speaker 8: it in a how do you do it.
• 29:47
  Speaker 10: In a fashion where the patient doesn't they don't lose
• 29:50
  Speaker 10: the information, they don't lose the interest from the time
• 29:53
  Speaker 10: that they prescribe the medication right where they understand what.
• 29:55
  Speaker 8: This journey's going to look like, what this journy's going
• 29:57
  Speaker 8: to feel like.
• 29:58
  Speaker 10: And so give health what we do as we engage
• 30:01
  Speaker 10: immediately and we make sure that the patient understands what
• 30:03
  Speaker 10: to expect, right.
• 30:04
  Speaker 8: So you set the right to.
• 30:05
  Speaker 10: Expectations and then the patient knows, the provider knows, the manufacturer,
• 30:08
  Speaker 10: a partner knows, they know what to expect right. And
• 30:11
  Speaker 10: when you do that, you can really set the standard
• 30:13
  Speaker 10: and you can understand what this is going to look like,
• 30:15
  Speaker 10: what this is going to feel like, and be a
• 30:17
  Speaker 10: really good partner throughout the process and throughout the journey.
• 30:20
  Speaker 3: About five maybe up to seven years ago, the advent
• 30:25
  Speaker 3: of AI really came into specialty pharmacy, whereas today it's
• 30:31
  Speaker 3: already proven. There's things that are working very well. There's
• 30:34
  Speaker 3: even standards being created to continue to build out where
• 30:39
  Speaker 3: AI is going to take Specialty pharmacy Gift health has
• 30:43
  Speaker 3: really leveraged the fusion of AI and the human experience
• 30:49
  Speaker 3: and humans being involved. We're not just leaving it just
• 30:52
  Speaker 3: to AI. Talk to us about the combination of AI
• 30:56
  Speaker 3: and then the human touch.
• 30:57
  Speaker 10: So we think it's incredibly important keep the human touch right,
• 31:01
  Speaker 10: but we also think it's really important to lead with
• 31:03
  Speaker 10: technology meet the patients where they are.
• 31:06
  Speaker 8: And in doing so, what we've found is there is.
• 31:08
  Speaker 10: An overwhelming number of patients that want to engage virtually right.
• 31:13
  Speaker 8: They want to engage in different ways.
• 31:14
  Speaker 10: They want to be they want to be found where
• 31:16
  Speaker 10: they are, they want to be found very quickly.
• 31:18
  Speaker 8: And in doing that, what it does is it.
• 31:19
  Speaker 10: Gives the patients optionality, and we see the patients engage.
• 31:22
  Speaker 10: They like they like the journey when you give them
• 31:25
  Speaker 10: that option and you can connect with them when they want,
• 31:28
  Speaker 10: where they want, and that's that's something that's really different
• 31:31
  Speaker 10: to the industry, and so finding that cadence, finding that
• 31:35
  Speaker 10: that opportunity to meet the patient where they are has
• 31:37
  Speaker 10: been really it's been a really good opportunity for us
• 31:42
  Speaker 10: to kind of change where the industry meets the patient.
• 31:45
  Speaker 3: I've talked with one of your colleagues and one of
• 31:49
  Speaker 3: the statements that they made that I wanted to ask
• 31:51
  Speaker 3: you more about was removing friction in the ecosystem and
• 31:57
  Speaker 3: making e commerce super simple and simplicity for the patient
• 32:01
  Speaker 3: to check out, and for automating data reporting and even
• 32:07
  Speaker 3: the predictive analytics that are available to us based on
• 32:09
  Speaker 3: how much data is out there. Talk to us about
• 32:11
  Speaker 3: how Gift Health has really leveraged AI and technology in
• 32:17
  Speaker 3: general to remove friction within the ecosystem.
• 32:21
  Speaker 10: Yeah, it's it's an interesting opportunity that you that you
• 32:24
  Speaker 10: have with the patient, you know, from the front end,
• 32:27
  Speaker 10: and so the way the way that we've leveraged that
• 32:29
  Speaker 10: is you find you find the patient very early in
• 32:33
  Speaker 10: the journey, right, and in finding that patient and understanding
• 32:36
  Speaker 10: how they want to engage in leveraging that, you know,
• 32:40
  Speaker 10: it gives you the unique ability to be be a
• 32:43
  Speaker 10: little bit different set, a little bit of a different
• 32:45
  Speaker 10: industry standard. And so we utilize the technology to bring
• 32:50
  Speaker 10: the script in very quickly right to engage the patient
• 32:53
  Speaker 10: before they have the opportunity to I don't want to
• 32:57
  Speaker 10: say lose interest, but I want to say before they
• 32:59
  Speaker 10: have the opportunity to misunderstand the journey right or look
• 33:03
  Speaker 10: at alternative options and feel like they're disconnected from their provider,
• 33:08
  Speaker 10: and so connecting with them early in taking the script
• 33:11
  Speaker 10: quickly has really allowed us to change, you know, the
• 33:15
  Speaker 10: whole dynamic and the whole timeline of what the patients expect.
• 33:18
  Speaker 10: And I think that's the biggest that's the biggest proponent
• 33:20
  Speaker 10: that we have, is changing the expectations that the patients
• 33:23
  Speaker 10: have because I think that in a lot of cases,
• 33:26
  Speaker 10: the patients feel like the journey is working against them,
• 33:29
  Speaker 10: and I think that they're feeling like Gift Health and
• 33:31
  Speaker 10: others are advocates for them.
• 33:33
  Speaker 3: Jeremy, I want to thank you for spending time with
• 33:35
  Speaker 3: us at the press booth here eighteen oh five at Asembiah.
• 33:39
  Speaker 3: I can't wait to follow up with you guys. I
• 33:41
  Speaker 3: have more questions, want to dig into how you're assisting
• 33:44
  Speaker 3: specialty pharmacy, specifically in the expansion of what Gift Health
• 33:48
  Speaker 3: is presenting to our patients. And thank you so much
• 33:51
  Speaker 3: for being here.
• 33:51
  Speaker 8: Absolutely really appreciate the time. Thank you again.
• 34:00
  Speaker 1: The Pharmacy Podcast Network would like to thank our sponsor
• 34:03
  Speaker 1: for supporting us at the twenty twenty six ASSEMBIA Summit.
• 34:06
  Speaker 1: Clearway Health is transforming specialty pharmacy for hospitals, health systems,
• 34:11
  Speaker 1: and the patients they serve. Clearway Health is more than
• 34:13
  Speaker 1: a specialty pharmacy partner. They are an extension of the
• 34:16
  Speaker 1: care team, working directly with hospitals and healthcare systems across
• 34:20
  Speaker 1: the country. Clearway healths plan, design, build and optimize specialty
• 34:25
  Speaker 1: pharmacy programs that improve access, reduce barriers, and deliver better
• 34:30
  Speaker 1: outcomes for patients with complex medical conditions. Through their embedded
• 34:34
  Speaker 1: care model, Clearway Health places pharmacists and patient liaisons directly
• 34:39
  Speaker 1: into clinical workflows, supporting providers with prior authorizations, financial assistance, coordination,
• 34:45
  Speaker 1: and patient education so care teams can focus on what
• 34:48
  Speaker 1: matters most the patient. Powered by advancing technology in real
• 34:52
  Speaker 1: time data insights, Clearway Health streamlines the entire medication journey
• 34:56
  Speaker 1: from prescription to adherents, ensuring patients receive the white medications
• 35:00
  Speaker 1: at the right time. Born out of Boston Medical Center
• 35:03
  Speaker 1: Health System, Clearway Health brings.
• 35:05
  Speaker 3: Real world experience and proven.
• 35:07
  Speaker 1: Results, helping health systems unlock new revenue streams while expanding
• 35:12
  Speaker 1: access to life changing specialty medications. As we head into
• 35:16
  Speaker 1: SMBA twenty twenty six, Clearway Health is leading the way
• 35:19
  Speaker 1: in refining specialty pharmacy where clinical excellence meets operational innovation.
• 35:24
  Speaker 1: Learn more at clearwayhealth dot com.
• 35:33
  Speaker 3: Joe Depento, head of Cell and Gene Advanced Therapies at McKesson,
• 35:37
  Speaker 3: back on the Pharmacy Podcast. It's so good to see you, Joe.
• 35:41
  Speaker 4: Great to see you, Todd. Thanks for having me.
• 35:43
  Speaker 3: We're here at the super Bowl of Specialty Pharmacy. So
• 35:46
  Speaker 3: excited to be here. This is probably one of my
• 35:48
  Speaker 3: favorite conferences to gather together. What do you like about assembia?
• 35:51
  Speaker 3: What do you like about coming here?
• 35:52
  Speaker 11: It's a never miss conference for me. I think I've
• 35:55
  Speaker 11: been coming for twenty years or so, and it's always
• 35:58
  Speaker 11: great to talk with like minded folks around some of
• 36:01
  Speaker 11: the challenges and opportunities and patient care and specialty pharmacy
• 36:06
  Speaker 11: continues to play such a really important role in patient care,
• 36:10
  Speaker 11: especially in my area.
• 36:11
  Speaker 4: So it's great.
• 36:12
  Speaker 11: It's great to see old friends, it's great to listen
• 36:14
  Speaker 11: to new topics. It's great to participate, and every year
• 36:18
  Speaker 11: I think it can't get bigger and better, and it
• 36:19
  Speaker 11: seems too well.
• 36:21
  Speaker 3: You've been on This Week in Pharmacy several times giving
• 36:24
  Speaker 3: us updates on selling gene and where we are. You're
• 36:28
  Speaker 3: moderating a panel at ASEMBIA this week on breaking through
• 36:32
  Speaker 3: reimbursement complexities for selling gene therapies. What's that conversation about you?
• 36:38
  Speaker 3: What are you hoping to obtain with that conference?
• 36:40
  Speaker 11: You know, I'm really excited to do this panel. We've
• 36:43
  Speaker 11: got a great bunch of presenters and subject matter experts,
• 36:48
  Speaker 11: everything from a physician who leads the Saracanon group as
• 36:53
  Speaker 11: well as HCA around sell gene advanced therapies. We have
• 36:57
  Speaker 11: a director of pharmacy for a big health plan as
• 37:01
  Speaker 11: well as a group of treatment centers Geisinger, and we
• 37:06
  Speaker 11: also have an innovative health economist CEO of Risk, a
• 37:11
  Speaker 11: company that just came out of stealth mode that's looking
• 37:14
  Speaker 11: at unique reimbursement and risk models. The space is complex
• 37:18
  Speaker 11: and the reimbursement challenges have been well documented and we
• 37:21
  Speaker 11: need to have different thinking to be able to tackle
• 37:23
  Speaker 11: that for patients to have better access. My goal in
• 37:26
  Speaker 11: this panel is to get that thinking moving in the
• 37:29
  Speaker 11: direction of solutions rather than laying out just the problem.
• 37:32
  Speaker 11: So I'm excited about it. It should be a fun panel.
• 37:35
  Speaker 11: I know I'm going to have a really interactive panel
• 37:37
  Speaker 11: because these panelists are just super knowledgeable and super personable.
• 37:42
  Speaker 3: I love that and that people that come here are
• 37:44
  Speaker 3: passionate about what they do. And we've been we've been
• 37:49
  Speaker 3: soaking in this for so long. We've seen changes all along.
• 37:52
  Speaker 3: I've seen changes in technology, I've seen changes in drug development.
• 37:56
  Speaker 3: What do you think has been the biggest challenges in
• 37:59
  Speaker 3: the selling gene space over the last twelve months?
• 38:03
  Speaker 11: So, selling gene therapy continues to evolve as a marketplace.
• 38:08
  Speaker 11: The science is well documented and is unbelievably strong. Where
• 38:14
  Speaker 11: we've had a challenge is moving from the science to
• 38:17
  Speaker 11: commercial patient access. I think we've made some progress with
• 38:20
  Speaker 11: the community expansion of moving selling gene therapy treatment out
• 38:24
  Speaker 11: of the teaching institutions to more of the community hospitals
• 38:27
  Speaker 11: and eventually the community clinics. So progress has been made there,
• 38:30
  Speaker 11: but look, it's still not to a point where the
• 38:33
  Speaker 11: patients have access that we'd all like to see where
• 38:38
  Speaker 11: they don't have to travel distances to go to see
• 38:41
  Speaker 11: a treatment center and that there's untethered access to these products.
• 38:45
  Speaker 11: Which is really important because the science is fantastic, So
• 38:49
  Speaker 11: how do we transition the clinical science to commercial patient
• 38:52
  Speaker 11: access is going to continue to be a focus. We're
• 38:55
  Speaker 11: making progress, I don't think fast enough that any of
• 38:58
  Speaker 11: us like it.
• 39:00
  Speaker 3: I know, in covering every aspect of our pharmacy industry,
• 39:04
  Speaker 3: it's the specialty sector that always has the issues around
• 39:08
  Speaker 3: reimbursement and getting a reimbursed. What makes selling gene therapy
• 39:13
  Speaker 3: reimbursement particularly challenging.
• 39:14
  Speaker 11: So there's a bus the challenges in selling gene The
• 39:18
  Speaker 11: barriers are multifactorial, right. Reimbursement's absolutely one plus in some
• 39:24
  Speaker 11: of these therapies. They're all a bit different. Cell therapies
• 39:27
  Speaker 11: are different than gene therapies, different price points, different dosing,
• 39:31
  Speaker 11: different approaches to patient care. We're starting to see more
• 39:34
  Speaker 11: and more of these approaches move out patient right, which
• 39:37
  Speaker 11: is great. The challenges we see on the reimbursement side,
• 39:41
  Speaker 11: or that typically are healthcare systems not set up for
• 39:45
  Speaker 11: reimbursement where there's a cost density component where you pay
• 39:49
  Speaker 11: up front and then you see the benefit over an
• 39:51
  Speaker 11: extended period of time. That's counter to our healthcare system
• 39:55
  Speaker 11: and reimbursement in our healthcare system. So I think we're
• 39:58
  Speaker 11: dealing with some of that. I think we're with making
• 40:00
  Speaker 11: sure the appropriate patients get the appropriate product, and I
• 40:03
  Speaker 11: think as an ecosystem, we're really fundamentally looking at how
• 40:07
  Speaker 11: do we best transition from all that clinical promise to
• 40:11
  Speaker 11: commercial access.
• 40:12
  Speaker 3: Yeah, exactly. So when you think of the field itself,
• 40:16
  Speaker 3: I get excited because I see pharmacists becoming specialist in
• 40:20
  Speaker 3: selling gene therapy and understanding it in its component and
• 40:24
  Speaker 3: its vertical But where do you where do you see
• 40:28
  Speaker 3: the field headed? What's the role of the pharmacist.
• 40:31
  Speaker 11: I think the farm. I've told you this in the
• 40:33
  Speaker 11: past when I've visited with you. I think the pharmacist
• 40:35
  Speaker 11: plays a critical role in the treatment team of selling
• 40:38
  Speaker 11: gene therapy patients. So the beauty of selling gene therapy.
• 40:43
  Speaker 11: That complexity is a clinical complexity, it's an operational complexity,
• 40:48
  Speaker 11: and it's a financial complexity.
• 40:50
  Speaker 3: Who best to.
• 40:51
  Speaker 11: Sort of connect all those dots and coordinate. But the
• 40:54
  Speaker 11: pharmacist who has that operational, that clinical and that financial
• 41:00
  Speaker 11: acumen to be able to help patients navigate that complexity,
• 41:05
  Speaker 11: to help health systems deliver more efficiently the products, and
• 41:09
  Speaker 11: to help biopharma make sure that as they approach the
• 41:12
  Speaker 11: commercialization of the products, it's being done in the right way.
• 41:15
  Speaker 11: So I think selling gene therapy is a high user
• 41:18
  Speaker 11: of pharmacy on a regular basis.
• 41:22
  Speaker 3: Joe, we always appreciate your insence, to appreciate you being
• 41:25
  Speaker 3: here at the SMBIA twenty twenty six coverage and hope
• 41:29
  Speaker 3: to have you back on this week in Pharmacy My pleasure.
• 41:31
  Speaker 12: Todd.
• 41:32
  Speaker 11: Always good to see you.
• 41:32
  Speaker 4: Thanks for having me.
• 41:34
  Speaker 3: All right, I want you to say, Hey, this is
• 41:36
  Speaker 3: Joe Dipinto and then you know whatever title and you're
• 41:40
  Speaker 3: listening to the Pharmacy Podcast Okay, ready in three two one.
• 41:44
  Speaker 11: Hey, this is Joe Dipinto ahead of Seal Genie. Advanced
• 41:47
  Speaker 11: Therapy is at McKesson and you're listening to the Pharmacy
• 41:50
  Speaker 11: Podcast Network.
• 41:56
  Speaker 3: Look who showed up at THESEMBIA twenty twenty six event.
• 42:00
  Speaker 3: Johnny Kello with match ORX.
• 42:02
  Speaker 12: How are you, hey, Todd, Thanks for having me, buddy.
• 42:04
  Speaker 12: I just was walking by and I knew you were
• 42:06
  Speaker 12: going to be here, so yeah, it's good to see you.
• 42:09
  Speaker 8: As always.
• 42:09
  Speaker 3: It's nice to see you too. I know that match
• 42:13
  Speaker 3: our X. The Power is in the Independent pharmacy space,
• 42:17
  Speaker 3: community pharmacy space, long term care. However, there are the
• 42:22
  Speaker 3: sprinkling of specialty pharmacies that are playing in areas where
• 42:26
  Speaker 3: match our X could kind of plug into talk to
• 42:29
  Speaker 3: us about your experience here and just being in this environment.
• 42:33
  Speaker 12: Yeah, so this has been exploratory for us. Yeah, you know,
• 42:38
  Speaker 12: it's interesting. It's a little bit of a different animal
• 42:42
  Speaker 12: than what we normally deal with on the independent side,
• 42:45
  Speaker 12: So we're just starting to get our feet wet with
• 42:48
  Speaker 12: specialty trying to understand is it a fit for us.
• 42:52
  Speaker 12: You know, one of the things that we've been really
• 42:54
  Speaker 12: conscious of over the years is not changing every shiny nickel,
• 42:58
  Speaker 12: staying focused on who we are what we do really well,
• 43:02
  Speaker 12: which is helping the independent space and bringing that at
• 43:06
  Speaker 12: every level.
• 43:07
  Speaker 3: And you know, kind of the reason.
• 43:09
  Speaker 12: We expanded with the feedback from our members into the
• 43:14
  Speaker 12: wholesale space. So you'll see now we've got fifteen secondary
• 43:18
  Speaker 12: wholesalers and just joined us, which we're really proud of
• 43:23
  Speaker 12: because considering the newbie that we are on that side
• 43:26
  Speaker 12: of the equation. Now over a year, we're only one
• 43:30
  Speaker 12: of I think two or three marketplaces that and chose
• 43:34
  Speaker 12: to be partnered with so again to the specialty piece.
• 43:40
  Speaker 12: We are again just kind of uncovering and understanding and
• 43:45
  Speaker 12: then if that's an opportunity where we can help in
• 43:47
  Speaker 12: that space, we'll go ahead and do it, you know,
• 43:50
  Speaker 12: in a diligent manner. But again today is just primarily exploratory,
• 43:55
  Speaker 12: although we've run into a lot of other partners here,
• 43:58
  Speaker 12: which great Assembia is such a big conference. You don't
• 44:02
  Speaker 12: have to say, hey, you're here just for one thing, sure,
• 44:05
  Speaker 12: because there's so many ancillary you know, vendors, partners that
• 44:09
  Speaker 12: are here.
• 44:10
  Speaker 3: That's why Armada Health, which was the company before becoming Assembia,
• 44:15
  Speaker 3: that's why they changed their name to Assembia because the
• 44:19
  Speaker 3: term assembia is to assemble together, to do more together
• 44:23
  Speaker 3: and be more powerful together for the patient than what
• 44:26
  Speaker 3: you are by yourself. So and that's your whole attitude
• 44:29
  Speaker 3: at MATUX is bringing people together. As a matter of fact,
• 44:32
  Speaker 3: for our podcast listeners listening to the Assembia post show,
• 44:36
  Speaker 3: mattu X has a special three part series out on
• 44:38
  Speaker 3: our network for this week in Pharmacy where you've brought
• 44:42
  Speaker 3: brought together several experts on DSSA and the politics of
• 44:46
  Speaker 3: where we are in pharmacy. So we really appreciate that support.
• 44:50
  Speaker 12: Yeah, no, I appreciate you guys getting the word out
• 44:52
  Speaker 12: because again, it continues to be an education to independence.
• 44:56
  Speaker 12: You know, everybody is still understanding what is an EPSIS file? Yeah,
• 45:00
  Speaker 12: what is DSCSA? Am I obligated to follow through on
• 45:06
  Speaker 12: each piece of that? And the short answer is yes,
• 45:08
  Speaker 12: there's carve outs and caveats, But come November twenty seventh
• 45:12
  Speaker 12: of this year, you really have to understand, you know,
• 45:16
  Speaker 12: what your requirements are as an independent, how you bring
• 45:19
  Speaker 12: product into your store, how you track that product. And
• 45:23
  Speaker 12: that's one of the reasons we partnered up with lspedia
• 45:26
  Speaker 12: is of we've become their exclusive marketplace reseller because we
• 45:31
  Speaker 12: believe in what they're doing.
• 45:33
  Speaker 8: We did it at a.
• 45:35
  Speaker 12: Price that's severely discounted to the retail price because we
• 45:39
  Speaker 12: want independents to, you know, make sure that they get
• 45:43
  Speaker 12: on board at the best opportunity, the most reasonable opportunity,
• 45:48
  Speaker 12: and understand what those needs are.
• 45:50
  Speaker 4: I think those kinds.
• 45:52
  Speaker 12: Of things are what we're doing today to educate people
• 45:55
  Speaker 12: before November twenty seventh.
• 45:57
  Speaker 4: And that's just one.
• 45:59
  Speaker 12: You know, we had Lisa Bernstein. Alisa, you know, I
• 46:01
  Speaker 12: would say is the foremost authority on d s CSA.
• 46:07
  Speaker 12: She led the FDA in the launch of the d
• 46:09
  Speaker 12: s CSA. Before she left the FDA, we had Cie Dino,
• 46:16
  Speaker 12: who really understands GCR. Again, another key component to buying
• 46:23
  Speaker 12: when you're buying for your pharmacy, understanding you know what's
• 46:26
  Speaker 12: contract and what you should be looking at outside of
• 46:29
  Speaker 12: contract because you're not maximizing savings by buying from your
• 46:34
  Speaker 12: primary or actually depleting.
• 46:37
  Speaker 4: But there's a balance, right.
• 46:39
  Speaker 12: We're not suggesting you do all your work with your primary,
• 46:43
  Speaker 12: but we're also suggesting that you'd be smart about where
• 46:46
  Speaker 12: you can buy outside of contract, because you know, if
• 46:49
  Speaker 12: it's three thousand, if it's five thousand, if it's ten
• 46:51
  Speaker 12: thousand dollars a month, it's your money. Take the time,
• 46:55
  Speaker 12: train your team, help you know, have them call us,
• 46:58
  Speaker 12: We'll help train the team. These are things that again
• 47:01
  Speaker 12: it's just those little things that people have to understand
• 47:05
  Speaker 12: to create processes for you know, every business is a people,
• 47:09
  Speaker 12: it's processes.
• 47:10
  Speaker 4: Those are the two key components.
• 47:12
  Speaker 12: And when you have the right person and you've got
• 47:14
  Speaker 12: good key, good process, I think you can make a
• 47:17
  Speaker 12: lot of those little things that people consider bothersome work
• 47:21
  Speaker 12: for your benefit. It's not a cost and it's an investment.
• 47:24
  Speaker 12: And so I think, you know, people get caught up
• 47:27
  Speaker 12: with day to day, but you know, we operate under
• 47:30
  Speaker 12: the EOS operating system and it tells you all the
• 47:32
  Speaker 12: time if you're working in your business, you're not working
• 47:35
  Speaker 12: on your business. So as independent pharmacies, sometimes you have
• 47:39
  Speaker 12: to pause, pull yourself off the you know, the counter
• 47:43
  Speaker 12: and filling scripts, and you have to work on your business,
• 47:46
  Speaker 12: not in your business. When you do that for that
• 47:50
  Speaker 12: ten twenty percent of your week, you're going to see
• 47:54
  Speaker 12: progress at the bottom line. If you're only working in
• 47:57
  Speaker 12: your business, what you're doing is you're sitting on a
• 48:00
  Speaker 12: hamster wheel and spinning and you're not really pulling yourself
• 48:04
  Speaker 12: off and looking from five thousand feet to really understand
• 48:09
  Speaker 12: and develop processes. And by the way, I don't care
• 48:13
  Speaker 12: if you're a newbie into the business or if you've
• 48:15
  Speaker 12: been a pharmacist for thirty five plus years. It's never
• 48:19
  Speaker 12: too late to learn how to work on your business.
• 48:23
  Speaker 3: So if I'm going to.
• 48:24
  Speaker 12: Leave you with anything, it's to have people recognize that
• 48:28
  Speaker 12: they should be working on their business as much as
• 48:31
  Speaker 12: they're working in their business.
• 48:33
  Speaker 3: Johnny kello match our X. Learn more at matchurx dot com. Johnny,
• 48:37
  Speaker 3: thanks for stopping by.
• 48:39
  Speaker 8: Thank you, Tod.
• 48:42
  Speaker 13: Hey there, this is Sean Griffin with your reck and
• 48:44
  Speaker 13: you're listening to the Pharmacy Podcast.
• 48:51
  Speaker 3: Sean, thanks for joining us at the SMBIA twenty twenty
• 48:54
  Speaker 3: six post show coverage. This is the Access to Pharmacy.
• 48:58
  Speaker 3: I call it the super Bowl of Specy pharmacy. And
• 49:02
  Speaker 3: your colleague was on with us, and she's just brilliant
• 49:05
  Speaker 3: and I love talking to I've talked to her several
• 49:07
  Speaker 3: years in a row. But talk to us about r
• 49:10
  Speaker 3: AS mission and some of the things that we were
• 49:14
  Speaker 3: talking about before we started recording was having standards for
• 49:19
  Speaker 3: providers to rely on so they don't have to have
• 49:21
  Speaker 3: any there's no guessing of what those standards are.
• 49:24
  Speaker 13: Yeah, so your's been around for thirty five years. So
• 49:26
  Speaker 13: we actually started back in utilization review. That's where the
• 49:29
  Speaker 13: you are in your AC comes from a utilization review.
• 49:32
  Speaker 13: And so we get together experts, we build programs, and
• 49:35
  Speaker 13: then we act like an independent quality auditor to come
• 49:38
  Speaker 13: in and actually check to make sure that things behind
• 49:40
  Speaker 13: the scenes match what people are saying. And so the
• 49:42
  Speaker 13: AI program was developed because we were watching AI come
• 49:45
  Speaker 13: into so many parts of healthcare, and the thing that
• 49:48
  Speaker 13: we were most concerned about wasn't the technical there's technical
• 49:51
  Speaker 13: standards and those sort of things. It's more about the
• 49:53
  Speaker 13: governance and the oversight and building the trust. One of
• 49:56
  Speaker 13: the analogies that I often use is if you think
• 49:58
  Speaker 13: about an AI tool, if it was a person, you'd
• 50:01
  Speaker 13: be wanting to credential them. You'd be wanting to know
• 50:04
  Speaker 13: where they went to school, You'd be wanting to know,
• 50:06
  Speaker 13: you know, how long do I have to keep an
• 50:07
  Speaker 13: eye on you since you're a new person or organization
• 50:09
  Speaker 13: before I trust you. Are you doing something incredibly high
• 50:12
  Speaker 13: risk or is it something low risk? And building an
• 50:15
  Speaker 13: oversight plan based upon the risk that's posed to patients?
• 50:19
  Speaker 13: And I think that right now, this is such a
• 50:21
  Speaker 13: gray area, and in AI it's very tough to tell
• 50:24
  Speaker 13: the good guys from bad guys. I always say, yeah,
• 50:26
  Speaker 13: you can't tell if it's coming from Google or six
• 50:28
  Speaker 13: guys in a garage. And so all of these things
• 50:31
  Speaker 13: are being sold. There's billions of dollars being thrown at
• 50:35
  Speaker 13: AI right now, and healthcare is a very fertile field
• 50:38
  Speaker 13: for organizations to come in and try and make money
• 50:40
  Speaker 13: off of their tools.
• 50:41
  Speaker 3: All right, So IRAQ has a mission ahead of you
• 50:46
  Speaker 3: to really define how far away from having a standard
• 50:50
  Speaker 3: just in guest estimations.
• 50:52
  Speaker 13: Well, we actually have a program. Our program came out
• 50:55
  Speaker 13: in September last year. It's the first AI in healthcare accreditation.
• 50:59
  Speaker 13: We had an advisory group who started the beginning of
• 51:01
  Speaker 13: last year. And when we got the advisory group together,
• 51:03
  Speaker 13: we were planning on building just one program. It was
• 51:05
  Speaker 13: actually going to be for users.
• 51:07
  Speaker 4: Of AI and healthcare.
• 51:08
  Speaker 13: And when we got the group together and it was
• 51:10
  Speaker 13: we had seventy applicants for twenty nine spots in our
• 51:13
  Speaker 13: advisory committee, everything from academic medical centers to pharma companies
• 51:16
  Speaker 13: to pharmacies to practicing physicians. They said, yes, we need
• 51:20
  Speaker 13: some standards around the users, but we also need one
• 51:22
  Speaker 13: for the developers. So our program actually has one for
• 51:25
  Speaker 13: the developers and one for the users. The developer one
• 51:28
  Speaker 13: is all about data integrity, it's about contracting, it's about transparency,
• 51:32
  Speaker 13: all the things that you would think about when it
• 51:34
  Speaker 13: comes to developers doing things in the right way. The
• 51:37
  Speaker 13: user one is about contracting. Where's the liability sit when
• 51:41
  Speaker 13: you sign a contract for an AI tool? Is it
• 51:43
  Speaker 13: being used for what it's designed for. Also, the business
• 51:46
  Speaker 13: reliability of the organization that built it. I mean to
• 51:49
  Speaker 13: be terrible to buy some AI tool and three months
• 51:52
  Speaker 13: later they go out of business and your left hang
• 51:53
  Speaker 13: and high and cry.
• 51:54
  Speaker 4: And so it's all.
• 51:55
  Speaker 13: About the sort of reliability of the organization's reliability of
• 51:58
  Speaker 13: the rollout. And also AI introduces some risks that we're
• 52:02
  Speaker 13: not used to in technology tools, drift hallucinations. You know,
• 52:07
  Speaker 13: AI changes depending on how it's implemented from from Monday
• 52:10
  Speaker 13: to Monday afternoon. It used to be when I was
• 52:13
  Speaker 13: a CMO, if I put in an order set in January,
• 52:15
  Speaker 13: it was the same order set in March, and now
• 52:18
  Speaker 13: it's changing by the afternoon with some of these AI tools.
• 52:21
  Speaker 13: And also there's a black box component to a lot
• 52:23
  Speaker 13: of AI tools. If you ask the AI experts, they say,
• 52:25
  Speaker 13: we're not exactly sure how it works. Well, we've never
• 52:29
  Speaker 13: let something come into medicine without an evidence base and
• 52:33
  Speaker 13: out without an understanding. You know, when I was practicing
• 52:35
  Speaker 13: as a physician, I said, show me the studies where
• 52:38
  Speaker 13: this is better than what I was doing before. Now
• 52:40
  Speaker 13: it's look at this really cool thing that happens in
• 52:42
  Speaker 13: this black box and I can't explain it to you,
• 52:45
  Speaker 13: but I'd like you to use that in the care
• 52:46
  Speaker 13: of your patients today, please.
• 52:48
  Speaker 3: All right, So calling out to specially pharmacies and specially
• 52:53
  Speaker 3: pharmacy organizations, is there anything that's novel? Is there anything
• 53:00
  Speaker 3: coming up that they should be paying attention to that
• 53:03
  Speaker 3: URAQ is putting a lot of emphasis or investment in.
• 53:06
  Speaker 13: Well, I think when you look at specialty pharmacy, I
• 53:08
  Speaker 13: mean there's an arms race going on right now, run
• 53:10
  Speaker 13: prior Authorizations, AGENTIC AI, all these sort of things, and
• 53:13
  Speaker 13: it's moving incredibly fast, and it's moving faster than regulations
• 53:17
  Speaker 13: are giving you safe lanes. And we're not here to
• 53:21
  Speaker 13: stifle innovation. We actually say, you know, if you're driving
• 53:23
  Speaker 13: a race car, you still wear a seat belt to
• 53:25
  Speaker 13: hold your in place. AI has no seat belts right now.
• 53:28
  Speaker 13: So we say that our program is about guardrails, not roadblocks,
• 53:31
  Speaker 13: and so we want you to we want it to
• 53:33
  Speaker 13: be done right. We think it holds tremendous promise, but
• 53:36
  Speaker 13: there's also known risks and there's unknown risks, and so
• 53:39
  Speaker 13: you know, take a look at our standards. They're out
• 53:41
  Speaker 13: at URAQ at dot org on our website, you can
• 53:44
  Speaker 13: see our standards of the glands that talk about everything
• 53:46
  Speaker 13: that we look at. For example, when we talk about
• 53:48
  Speaker 13: oversight of an AI tool, we talk about technical oversight,
• 53:51
  Speaker 13: clinical oversight, and ethical oversight. And I think that you know,
• 53:55
  Speaker 13: we all see the horror stories that pop up on
• 53:57
  Speaker 13: the news about somebody falling in love with their chat bot,
• 54:00
  Speaker 13: or somebody using some tool to plan their school shooting
• 54:03
  Speaker 13: or something like that, and this is just a dangerous
• 54:06
  Speaker 13: area right now. And we think in this wild West
• 54:08
  Speaker 13: that you're actually could be a trusted sheriff. We say
• 54:11
  Speaker 13: that we can't have the wolves guarding the chickens right now,
• 54:14
  Speaker 13: and so having somebody who sits outside, who's looked at
• 54:17
  Speaker 13: all the best practices, the forty five or whatever best
• 54:20
  Speaker 13: practices that are out there, and brings the trust that
• 54:23
  Speaker 13: you have for ur EK and the role that we
• 54:24
  Speaker 13: have played into specialty pharmacy and to all the other
• 54:27
  Speaker 13: areas of healthcare is incredibly important. A lot of the
• 54:30
  Speaker 13: concern right now also is as people try and control
• 54:32
  Speaker 13: this space, there's concerned about a patchwork where that patchwork be.
• 54:35
  Speaker 13: Different states have different rules, different emphasises that they follow.
• 54:39
  Speaker 13: We're concerned about a patchwork where there's going to be
• 54:41
  Speaker 13: one set of rules for doctors, one set of rules
• 54:43
  Speaker 13: for hospitals, one set of rules for pharmacies, and then
• 54:46
  Speaker 13: you don't even know what you're dealing with. And so
• 54:49
  Speaker 13: we just think that having an accreditation for AI in
• 54:52
  Speaker 13: healthcare that applies to anybody in healthcare from an organization
• 54:55
  Speaker 13: that was best in business for accreditation the past two
• 54:58
  Speaker 13: years and has been trusted, we think that it's filling
• 55:00
  Speaker 13: a gap.
• 55:02
  Speaker 3: Sean Griffin, I want to thank you. I want to
• 55:04
  Speaker 3: thank your Iraq for spending time with us at Ascembia
• 55:08
  Speaker 3: twenty twenty six. I can't wait to have you guys back.
• 55:10
  Speaker 3: I want to learn more and I have my own
• 55:13
  Speaker 3: standardization that we're trying to work with. Talked to your
• 55:18
  Speaker 3: team a little bit about, but I'll definitely follow up
• 55:20
  Speaker 3: with you on it.
• 55:21
  Speaker 13: We should have some people get through the accreditation by
• 55:24
  Speaker 13: June and we'll be doing a whole wave of publicity
• 55:26
  Speaker 13: when that comes out.
• 55:27
  Speaker 3: I'll be there. Thank you.
• 55:28
  Speaker 13: Thanks